Frédéric Frippiat

Cliniques Universitaires Saint-Luc

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Michel Moutschen

University of Liège

Philippe Léonard

University of Liège

Christelle Meuris

University of Liège

Jean‐Baptiste Giot

University of Liège

Nathalie Layios

Centre Hospitalier Universitaire de Liège

Gilles Darcis

University of Liège

Pierre Damas

Centre Hospitalier Universitaire de Liège

Bernard Lambermont

Centre Hospitalier Universitaire de Liège

Anne-Sophie Sauvage

Centre Hospitalier Universitaire de Liège

Nathalie Maes

University of Liège

Cooperative Institutions

University of Edinburgh

380

University of Siena

359

International Severe Acute Respiratory and Emerging Infection Consortium

University of Oxford

Roslin Institute

St Mary's Hospital

University of Liverpool

210

National Institute for Health Research

204

University of Liège

191

Centre for Inflammation Research

174

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Continuous infusion, therapeutic drug monitoring and outpatient parenteral antimicrobial therapy with ceftazidime/avibactam: a retrospective cohort study

Journal of Global Antimicrobial Resistance (2021)

Véronique Goncette Nathalie Layios Julie Descy Frédéric Frippiat

Based on recent pharmacokinetic/pharmacodynamic (PK/PD) evidence, continuous-infusion (CI) β-lactam administration is increasingly recommended for serious infections. Since 2016, the combination ceftazidime/avibactam (CAZ/AVI) is administered as per the manufacturer's instructions as an intermittent infusion of 2.5 g every 8 h. Thus, CI has not yet been evaluated in clinical trials.We aimed to evaluate the use of CI of CAZ/AVI in a retrospective case series from December 2016 to October 2019. All isolates displayed in vitro susceptibility to CAZ/AVI according to EUCAST definitions. Patients were initially given CAZ/AVI as CI of 5 g every 12 h, and dosages were adjusted according to therapeutic drug monitoring of ceftazidime with a therapeutic goal of ≥4-5 × MIC in plasma and/or at the site of infection.CAZ/AVI was administered by CI in 10 patients with infections mainly caused by multidrug-resistant Pseudomonas aeruginosa (54.5%) and Klebsiella pneumoniae (36.4%). Bacteraemia occurred in 30% of cases. Sepsis or septic shock was present in 20% of cases. CAZ/AVI was used as monotherapy in 60% of cases. Clinical cure and microbiological eradication were achieved in 80% and 90% of cases, respectively. The 30-day mortality after CAZ/AVI treatment onset was 10%. The therapeutic goals of ≥4-5 × MIC in plasma and/or at the site of infection were achieved in 100% and 87.5% of cases, respectively, without adverse events.Despite a limited number of patients, CI of CAZ/AVI provided promising results after optimisation of PK/PD parameters both in plasma and at the site of infection.

Ceftazidime/avibactam

Pharmacodynamics

Avibactam

Therapeutic Drug Monitoring

Dose

Beta-Lactamase Inhibitors

10.1016/j.jgar.2021.04.015

Cite

Citations (29)

[New treatments of infectious diseases over the last ten years].

PubMed (2007)

Giot Jb Mukeba Tshialala D Mayasi Ngongo N Frédéric Frippiat Philippe Léonard

This review focuses on new antibiotics, particularly for gram-positive infections, new antiretroviral drugs, new treatment of fungal infections and indications of miltefosine in the treatment of leishmaniasis.

Source

Cite

Citations (0)

[Hooping cough in adults, think about it!].

PubMed (2013)

A Toukouki Frédéric Frippiat Nicolas Frusch Paul Leonard P. Caprasse

We report the case of a 47 year old patient who had been suffering from persistent cough for more than three weeks. Patient coughed predominantly during night time, without fever. The amoxicillin-clavulanic acid initially prescribed was not effective. A series of complementary investigations were performed before serology finally identified Bordetella pertussis infection after two months of symptoms which improved slowly without evident benefit of macrolide treatment. The diagnosis of whooping cough was also established for the wife of the patient with fast resolution of the symptoms after rapid unset of treatment with macrolides.

Whooping cough

Throat

Source

Cite

Citations (2)

Qu’avons-nous appris de la pandémie de grippe de 2009 ?

Marc Vanmeerbeek Philippe Burette Didier Giet Frédéric Frippiat Sébastien Brunet

Source

Cite

Citations (0)

Causal Relationship between Neuropathy and Prolonged Linezolid Use

Clinical Infectious Diseases (2004)

Frédéric Frippiat G. Derue

Linezolid

10.1086/422147

Cite

Citations (20)

Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study

Journal of Antimicrobial Chemotherapy (2014)

Frédéric Frippiat Flora T. Musuamba Laurence Seidel Adelin Albert Raphaël Denooz

The objective of this study was to propose an optimal treatment regimen of meropenem in critically ill patients with severe nosocomial pneumonia.Among 55 patients in intensive care treated with 1 g of meropenem every 8 h for severe nosocomial pneumonia, 30 were assigned to intermittent infusion (II; over 0.5 h) and 25 to extended infusion (EI; over 3 h) groups. Based on plasma and epithelial lining fluid (ELF) concentrations determined at steady-state, pharmacokinetic modelling and Monte Carlo simulations were undertaken to assess the probability of attaining drug concentrations above the MIC for 40%-100% of the time between doses (%T > 1-fold and 4-fold MIC), for 1 or 2 g administered by either method.Penetration ratio, measured by the ELF/plasma ratio of AUCs, was statistically higher in the EI group than in the II group (mean ± SEM: 0.29 ± 0.030 versus 0.20 ± 0.033, P = 0.047). Considering a maximum susceptibility breakpoint of 2 mg/L, all dosages and modes of infusions achieved 40%-100% T > 1-fold MIC in plasma, but none did so in ELF, and only the 2 g dose over EI achieved 40%-100% T > 4-fold MIC in plasma.The optimum regimen to treat severe nosocomial pneumonia was 2 g of meropenem infused over 3 h every 8 h. This regimen achieved the highest pharmacodynamic targets both in plasma and in ELF.

Regimen

Pharmacodynamics

Dose

10.1093/jac/dku354

Cite

Citations (63)

Les maladies inflammatoires chroniques intestinales : de la génétique au traitement

RMLG. Revue médicale de Liège (2007)

Kalleshwar Chandrika Patricia Dellot Frédéric Frippiat Jean‐Baptiste Giot Philippe Léonard

Les maladies inflammatoires chroniques intestinales (MICI), la maladie de Crohn (MC) et la rectocolite ulcero-hemoragique, sont des maladies assez frequentes dans nos regions et grevee d'une importante alteration de la qualite de vie. Il est maintenant bien etabli qu'il s'agit de traits complexes multifactoriels polygeniques. Les nouveaux traitements biologiques developpes dans ces maladies sont potentiellement tres efficaces, mais sont aussi tres couteux et presentent une toxicite potentielle. Le ciblage des patients a traiter par differents outils, notamment la pharmacogenetique est un objectif important des annees a venir. Dans le present article, les auteurs retracent les resultats obtenus au cours des 10 dernieres annees au CHU de Liege, a la fois dans l'identification de genes de predisposition aux MICI et dans la pharmacogenetique de l'infliximab dans la MC.A travers cet article, l'evolution des strategies de recherche dans ce domaine est egalement abordee.

Crohn disease

Source

Cite

Citations (0)

Corticosteroids in bacterial meningitis: what's new, what's true?

PubMed (2012)

Frédéric Frippiat Michel Moutschen

10.2143/acb.66.6.2062616

Cite

Citations (1)

Usefulness of procalcitonin for the decision of antibiotic treatment in ICU patients

Intensive Care Medicine (2009)

Nathalie Layios Bernard Lambermont Didier Ledoux Philippe Morimont Paul Massion

Procalcitonin

Pain medicine

Source

Cite

Citations (3)

[Endocarditis of mitral and aortic prosthetic heart valves caused by Aggregatibacter aphrophilus].

PubMed (2017)

Benjamin Deleixhe Frédéric Frippiat Philippe Léonard Nadia Withofs Cécile Meex

We present the case of an acute endocarditis of mitral and aortic prosthetic heart valves caused by Aggregatibacter aphrophilus (Haemophilus aphrophilus-paraphrophilus). This third report in the literature emphasizes the diagnostic work-up and the role of positron emission tomography combined with computed tomography in this setting. The specificities of endocarditis due to the HACEK group (Haemophilus spp., Aggregatibacter, Cardiobacterium hominis, Eikenella corrodens and Kingella spp.) and the specific microbiological data and therapeutic options pertinent to this germ are discussed.Nous rapportons la troisième observation clinique de la littérature d’une endocardite sur prothèses mécaniques mitrale et aortique due à l’Aggregatibacter aphrophilus (Haemophilus aphrophilus-paraphrophilus). Le pathogène récemment rebaptisé Aggregatibacter aphrophilus fait partie du groupe HACEK (Haemophilus spp., Aggregatibacter, Cardiobacterium hominis, Eikenella corrodens and Kingella spp.) impliqué dans des endocardites valvulaires de diagnostic difficile. Cette histoire clinique est l’occasion d’une revue de la littérature et des spécificités de ce pathogène. Elle met en exergue la contribution de la tomographie à émission de positons combinée à une tomodensitométrie dans le diagnostic et le suivi. Elle démontre, avec un recul de plus de deux ans, l’efficacité du traitement médical dans certaines endocardites sur prothèse.

Eikenella corrodens

Source

Cite

Citations (2)